Cresp 40 mcg Injection is a sterile, preservative-free injectable formulation containing Darbepoetin alfa, a synthetic version of the naturally occurring hormone erythropoietin. It stimulates the bone marrow to produce red blood cells, thereby increasing hemoglobin levels in the blood.
Cresp 40 mcg is a prefilled syringe containing 0.4 mL of Darbepoetin alfa, which stimulates the bone marrow to produce red blood cells. It is primarily used in:
1.Anemia due to chronic kidney disease
2.Anemia related to chemotherapy for certain cancers
Mechanism of Action
Darbepoetin alfa works by binding to erythropoietin receptors on red blood cell precursors in the bone marrow. This binding stimulates the survival, proliferation, and differentiation of these precursor cells into mature red blood cells, thereby increasing the oxygen-carrying capacity of the blood .
Dosage and Administration
Chronic Kidney Disease (CKD):
1.Initial dose: 0.45 mcg/kg body weight administered subcutaneously once every week
2.Maintenance dose: Adjusted based on hemoglobin levels, aiming to maintain levels between 10–12 g/dL.
Chemotherapy-Induced Anemia:
1.Initial dose: 2.25 mcg/kg body weight administered subcutaneously once every week
2.Maintenance dose: Adjusted as per hemoglobin levels
Side Effects
Common side effects may include:
1.Injection site reactions: Pain, redness, or swelling
2.Systemic effects: Headache, nausea, fatigue, dizziness, and muscle pain
3.Cardiovascular: High blood pressure, chest pain, and shortness of breath
4.Neurological: Seizures, especially during the initial stages of treatment
5.Other: Edema (swelling), cough, and abdominal pain
